Cancer de la prostate localisé : l'IRM endorectale à 1,5 Tesla améliore-t-elle la sélection des patients en vue d'une surveillance active ?

Endorectal MR at 1.5 Tesla with pelvic-phased array coil should be considered when selecting patients for active surveillance in the management of prostate cancer. A criterion based upon MR and core biopsy findings, called “T3MR ± NSP > 1” may represent an exclusion citeria due to its ability to predict significant tumor.